Immunomedics, Inc. Reports Advances With New Imaging Agent Developments for Positron Emission Tomography

SAN ANTONIO, June 8, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that 4 studies, using the Company's recently patented peptide labeling method with the radioisotope fluorine-18 (18F), for improved positron emission tomography (PET) imaging of diseases, were presented at the 2011 Annual Meeting of the Society of Nuclear Medicine.